{
    "medicine_id": "e232808ed4b5567bf974f86987542df09509728c",
    "platform_id": "9881",
    "metadata": {
        "name": "Darunavir Mylan 400 mg film coated tablets Darunavir Mylan 800 mg film coated tablets",
        "composition": "Darunavir Mylan 400 mg film coated tablets Each film coated tablet contains 400 mg of darunavir Darunavir Mylan 800 mg film coated tablets Each film coated tablet contains 800 mg of darunavir For the full list of",
        "clinical_particulars": {
            "therapeutic_indications": "Darunavir co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus HIV 1 infection Darunavir co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus HIV 1 infection in adults and adolescents aged 12 years and older weighing at least 40 kg see section 4 2 Darunavir Mylan 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of HIV 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are 6 L In deciding to initiate treatment with darunavir in such ART experienced patients genotypic testing should guide the use of darunavir see sections 4 2 4 3 4 4 and 5 1",
            "contraindications": {
                "disease": "Hypersensitivity to the active substance or to any of the excipients listed in section 6 1 Patients with severe Child Pugh Class C hepatic impairment Concomitant treatment with any of the following medicinal products given the expected decrease in plasma concentrations of darunavir ritonavir and cobicistat and the potential for loss of therapeutic effect see sections 4 4 and 4 5 Applicable to darunavir boosted with either ritonavir or cobicistat The combination product lopinavir ritonavir see section 4 5 The strong CYP3A inducers rifampicin and herbal preparations containing St John s wort Hypericum perforatum Co administration is expected to reduce plasma concentrations of darunavir ritonavir and cobicistat which could lead to loss of therapeutic effect and possible development of resistance see sections 4 4 and 4 5 Applicable to darunavir boosted with cobicistat not when boosted with ritonavir Darunavir boosted with cobicistat is more sensitive for CYP3A induction than darunavir boosted with ritonavir Concomitant use with strong CYP3A inducers is contraindicated since these may reduce the exposure to cobicistat and darunavir leading to loss of therapeutic effect Strong CYP3A inducers include e g carbamazepine phenobarbital and phenytoin see sections 4 4 and 4 5 Darunavir boosted with either ritonavir or cobicistat inhibits the elimination of active substances that are highly dependent on CYP3A for clearance which results in increased exposure to the co administered medicinal product Therefore concomitant treatment with such medicinal products for which elevated plasma concentrations are associated with serious and or life threatening events is contraindicated applies to darunavir boosted with either ritonavir or cobicistat These active substances include e g alfuzosin amiodarone bepridil dronedarone ivabradine quinidine ranolazine astemizole terfenadine colchicine when used in patients with renal and or hepatic impairment see section 4 5 ergot derivatives e g dihydroergotamine ergometrine ergotamine methylergonovine elbasvir grazoprevir cisapride dapoxetine domperidone naloxegol lurasidone pimozide quetiapine sertindole see section 4 5 triazolam midazolam administered orally for caution on parenterally administered midazolam see section 4 5 sildenafil when used for the treatment of pulmonary arterial hypertension avanafil simvastatin lovastatin and lomitapide see section 4 5 ticagrelor see section 4 5",
                "pregnancy": "Applicable",
                "machine_ops": "Applicable",
                "excipients": "Silica, colloidal anhydrous;Cellulose microcrystalline;Crospovidone;Sodium starch glycolate;Hypromellose;Magnesium stearate;Polyvinyl alcohol partially hydrolysed;Titanium dioxide (E171);Macrogol;Talc",
                "incompatibilities": "Not applicable."
            }
        },
        "revision_date": "2022-11-12"
    }
}